ArticleDiscover oncology2025
Zwilch kinetochore protein affects the prognosis of cancer patients by participating in cell proliferation, enhancing cell communication, and reshaping the tumor microenvironment.
Article in Discover oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundZwilch Kinetochore Protein(ZWILCH) has been reported to prevent cells from prematurely exiting mitosis. However, the underlying mechanisms or involvement of ZWILCH in the tumor immune microenvironment in various cancers remain largely unknown.
methodsGeneralized dysregulation of ZWILCH was observed through the whole transcriptome analysis in this study. The spatial transcriptome analysis was utilized to identify expressed regions of ZWILCH. Next, cells that mainly expressed ZWILCH in the tumor microenvironment were determined using the single-cell transcriptome analysis. Also, the "cellchat" R package was applied to estimate the effect of ZWILCH on malignant cell communication. Combining multiple analytic approaches including GSEA, GSVA, KEGG enrichment analysis, and Aucell, with TCPA functional protein data, Genome-wide CRISPR screening, potential functions of ZWILCH and the pathways in which ZWILCH participated were thoroughly exploited. Univariate Cox regression analysis calculated the association between ZWILCH and cancer patients' adverse outcomes.
resultsZWILCH is universally highly expressed in tumors. The spatial transcriptome analysis showed that ZWILCH overexpression comes from the tumoral region or mixed tumoral region. At the single-cell level, ZWILCH is chiefly expressed by malignant cells and proliferative T cells. The expression of ZWILCH mRNA is positively correlated with cell proliferation, repair of DNA damage, and cell cycle score. Plenty of metabolic pathways are inhibited in patients with high expression of ZWILCH. Moreover, after ZWILCH knockout, a large number of cancer cell lines are stagnated, inhibited, or died. Additionally, the malignant cells with positive expression of ZWILCH have a stronger ability for cell communication. In short, ZWILCH is meant to be a risk factor for clinical outcomes of multiple tumors.
conclusionsZWILCH is a promising therapeutic target that influences patient prognosis by participating in cell proliferation, cell communication, and reshaping the tumor microenvironment across different cancers.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.